* AUREUS PHARMA *
2000 - IDF
Paris
www.aureus-pharma.com Contract, Knowledge
Key words: Bioinformatics, Knowledge management, Molecular modeling, Data structuring, AurSCOPE, AurPROFILE
Mission: to provide knowledge management solutions to accelerate life science discovery for third parties
Clients: Pharmaceutical industry, Biotechs
info@aureus-pharma.com
Age: 10 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Start-up |
Managing Dir.-CEO: Theodosiou (Jason) [born 1959, Ph.D. organic chemistry, MBA Sup de Co Paris, ex-MDL Information Systems, EMAX/SciQuest, LION Bioscience, Elsevier
Sc.Dir.-CSO: Petitet (François) [Pharm.D., Ph.D.]
Fin.Dir.-CFO: Riot-Lamotte (Laurence)
BusDev:
Financers (Hist.): Bioam, AXA, FCJE (CDC), Matignon, OTC-AM | Turnover (M€) : 1.5 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Data
Position : Subcontractor
Company confirm : neutral |
History | DATE | MILESTONE | TYPE | TIME | | 2010 .02 | Licensing-out of DDI Project 2009 to Sanofi-Aventis | LICOUT | [10 years] |
| 2008 .08 | Launch of new software solution AurPROFILER (to rapidly evaluate target, cell and drug profiles using bio-assays) | MKTG | [8 years] |
| 2007 .11 | Licensing-out of Aurscope GPCR to BMS (renewal) | LICOUT | [7 years] |
| 2002 .11 | Licensing-out to Servier and Aventis | LICOUT | [2 years] |
| 2006 .12 | Nomination : Jason Theodosiou, new CEO, André Michel, founder, moved to supervisory board | ORGN | [6 years] |
| 2004 .10 | 1st round-financing : 3.0 M€, by OTC A.M., AXA P.E., and previous shareholders | RFINA | [4 years] |
| 2002 .01 | Company (holding of Aureus as an SCP) founded by Dr André Michel | ORGF | [2 years] |
| 2000 .09 | Seed financing : 0.8 M€, by Bioam | SFIN | [0 year] |
| 2000 .01 | Company founded by Dr André Michel [born 1944, CEO, Ph.D. chemistry, Namur, ex-Servier, Neokimia] | ORGF | [0 year] | Actualisation / Updating: 08-Mars-2010 |
|
